Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells

In the present study we show that histone deacetylase inhibitors (HDACIs) enhance the anti-tumor effects of melanoma differentiation associated gene-7/interleukin 24 (mda-7/IL-24) in human renal carcinoma cells. Similar data were obtained in other GU tumor cells. Combination of these two agents resulted in increased autophagy that was dependent on expression of ceramide synthase 6, with HDACIs enhancing MDA-7/IL-24 toxicity by increasing generation of ROS and Ca2+. Knock down of CD95 protected cells from HDACI and MDA-7/IL-24 lethality. Sorafenib treatment further enhanced (HDACI + MDA-7/IL-24) lethality. Anoikis resistant renal carcinoma cells were more sensitive to MDA-7/IL-24 that correlated with elevated SRC activity and tyrosine phosphorylation of CD95. We employed a recently constructed serotype 5/3 adenovirus, which is more effective than a serotype 5 virus in delivering mda-7/IL-24 to renal carcinoma cells and which conditionally replicates (CR) in tumor cells expressing MDA-7/IL-24 by virtue of placing the adenoviral E1A gene under the control of the cancer-specific promoter progression elevated gene-3 (Ad.5/3-PEG-E1A-mda-7; CRAd.5/3-mda-7, Ad.5/3-CTV), to define efficacy in renal carcinoma cells. Ad.5/3-CTV decreased the growth of renal carcinoma tumors to a significantly greater extent than did a non-replicative virus Ad.5/3-mda-7. In contralateral uninfected renal carcinoma tumors Ad.5/3-CTV also decreased the growth of tumors to a greater extent than did Ad.5/3-mda-7. In summation, our data demonstrates that HDACIs enhance MDA-7/IL-24-mediated toxicity and tumor specific adenoviral delivery and viral replication of mda-7/IL-24 is an effective pre-clinical renal carcinoma therapeutic.

[1]  P. Fisher,et al.  Enhanced delivery of mda‐7/IL‐24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the apogossypol derivative BI‐97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells , 2012, Journal of cellular physiology.

[2]  S. Milstien,et al.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy , 2012, Oncogene.

[3]  D. Dhar,et al.  Syrian hamster tumor model to study oncolytic Ad5-based vectors. , 2012, Methods in molecular biology.

[4]  S. Awasthi,et al.  Novel Anti-cancer Compounds for Developing Combinatorial Therapies to Target Anoikis-Resistant Tumors , 2011, Pharmaceutical Research.

[5]  P. Fisher,et al.  Autophagy switches to apoptosis in prostate cancer cells infected with melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) , 2011, Autophagy.

[6]  P. Fisher,et al.  A Serotype 5/3 Adenovirus Expressing MDA-7/IL-24 Infects Renal Carcinoma Cells and Promotes Toxicity of Agents That Increase Ros and Ceramide Levels , 2011, Molecular Pharmacology.

[7]  P. Fisher,et al.  Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery , 2010, Cancer biology & therapy.

[8]  L. Ellis,et al.  Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies , 2010, Pharmaceuticals.

[9]  D. Häussinger,et al.  Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells , 2010, Molecular Cancer Therapeutics.

[10]  P. Fisher,et al.  Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Z. Su,et al.  Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells , 2010, Cancer Gene Therapy.

[12]  P. Fisher,et al.  PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. , 2010, Cancer research.

[13]  P. Fisher,et al.  Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24–Induced Killing in Ovarian Carcinoma Cells , 2010, Molecular Pharmacology.

[14]  P. Fisher,et al.  Ceramide plays a prominent role in MDA‐7/IL‐24‐induced cancer‐specific apoptosis , 2009, Journal of cellular physiology.

[15]  P. Tofilon,et al.  Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. , 2010, Neoplasia.

[16]  Jessica E. Bolden,et al.  Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. , 2009, Cancer letters.

[17]  P. Fisher,et al.  MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism , 2009, Molecular Cancer Therapeutics.

[18]  Caterina Giannini,et al.  Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Fisher,et al.  Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24 , 2009, Cancer biology & therapy.

[20]  John D. Roberts,et al.  Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation , 2008, Clinical Cancer Research.

[21]  P. Fisher,et al.  Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis , 2008, Proceedings of the National Academy of Sciences.

[22]  P. Fisher,et al.  Characterization of infectivity of knob-modified adenoviral vectors in glioma , 2008, Cancer biology & therapy.

[23]  Z. Su,et al.  A cancer terminator virus eradicates both primary and distant human melanomas , 2008, Cancer Gene Therapy.

[24]  P. Fisher,et al.  Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells , 2008, Molecular Cancer Therapeutics.

[25]  S. Inoue,et al.  mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). , 2007, International journal of oncology.

[26]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[27]  P. Fisher,et al.  Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. , 2007, Cancer research.

[28]  R. Vento,et al.  SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib , 2007, Apoptosis.

[29]  P. Fisher,et al.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. , 2006, Pharmacology & therapeutics.

[30]  P. Fisher,et al.  BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. , 2006, Cancer research.

[31]  Z. Su,et al.  Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2 , 2006, Oncogene.

[32]  J. Cheville,et al.  Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. , 2005, The Journal of urology.

[33]  G. Duigou,et al.  Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Yuan Zhang,et al.  Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  C. D. Krause,et al.  Interleukin-10 and related cytokines and receptors. , 2004, Annual review of immunology.

[36]  S. Grant,et al.  Histone deacetylase inhibitors in clinical development , 2004, Expert opinion on investigational drugs.

[37]  D. Curiel,et al.  Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. , 2002, Cancer research.

[38]  L. Broemeling,et al.  Loss of MDA-7 expression with progression of melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Pestka,et al.  Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties , 2001, Oncogene.

[40]  A. Sahin,et al.  Down‐regulated melanoma differentiation associated gene (mda‐7) expression in human melanomas , 2001, International journal of cancer.

[41]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Z. Su,et al.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Z. Su,et al.  The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Z. Su,et al.  Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. , 1995, Oncogene.